{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:12:33Z","timestamp":1790014353238,"version":"4.0.1"},"reference-count":99,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim of this clinical consensus statement of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases, the Working Group on Cardiovascular Pharmacotherapy, the Working Group on Pulmonary Circulation &amp; Right Ventricular Function, and the European Society of Vascular Medicine is to summarize existing evidence on lipid-lowering therapy (LLT) in primary and secondary prevention of venous thromboembolism (VTE).<\/jats:p>\n                  <jats:p>VTE, which comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), shares common risk factors with atherosclerotic cardiovascular disease (ASCVD). While anticoagulation is the mainstay in the management of patients with VTE, it may be appropriate to define LLT as a risk modifier in primary prevention of VTE in populations at high cardiovascular risk. In patients with VTE, assessment of cardiovascular risk factors, including lipid levels, is commonly part of routine cardiovascular care in accordance with existing ESC Guidelines.<\/jats:p>\n                  <jats:p>Finally, this clinical consensus statement highlights the gaps in evidence and the need for large-scale studies directly investigating the role of LLT in secondary prevention of recurrent VTE in high-risk populations.<\/jats:p>","DOI":"10.1093\/eurjpc\/zwag481","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:11:42Z","timestamp":1788948702000},"source":"Crossref","is-referenced-by-count":0,"title":["Lipid-lowering therapy in venous thromboembolism: A Clinical Consensus Statement of the ESC Working Group on Aorta and Peripheral Vascular Diseases, the ESC Working Group on Cardiovascular Pharmacotherapy, the ESC Working Group on Pulmonary Circulation &amp; Right Ventricular Function, and the European Society of Vascular Medicine (ESVM)"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9243-1761","authenticated-orcid":false,"given":"Christine","family":"Espinola-Klein","sequence":"first","affiliation":[{"name":"Department of Angiology, Center of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-8995","authenticated-orcid":false,"given":"Christian","family":"Heiss","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Surrey , Guildford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Brodmann","sequence":"additional","affiliation":[{"name":"Division of Angiology, Medical University Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gary","sequence":"additional","affiliation":[{"name":"Division of Angiology, Medical University Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2022-6440","authenticated-orcid":false,"given":"Lucia","family":"Mazzolai","sequence":"additional","affiliation":[{"name":"Department of Angiology, Lausanne University Hospital (CHUV) , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bura-Riviere","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Toulouse University Hospital , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Linnemann","sequence":"additional","affiliation":[{"name":"Department of Angiology, Center of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-9818","authenticated-orcid":false,"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Princess Grace Hospital ,","place":["Monaco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 F Rodriguez","family":"Palomares","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Vall d\u2019Hebron Hospital Universitari, Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona ,","place":["Spain"]},{"name":"Cardiovascular Diseases, Vall d\u2032Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra ,","place":["Spain"]},{"name":"CIBER de Enfermedades Cardiovasculares, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederikus A","family":"Klok","sequence":"additional","affiliation":[{"name":"Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-9761","authenticated-orcid":false,"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[{"name":"VIVIT-Institute, Academic Teaching Hospital Feldkirch , Feldkirch ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Belch","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Research, Ninewells Hospital and Medical School , Dundee ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-404X","authenticated-orcid":false,"given":"Mislav","family":"Vrsalovic","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University of Zagreb School of Medicine, University Hospital Centre Sestre Milosrdnice , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-5355","authenticated-orcid":false,"given":"Oliver","family":"Schlager","sequence":"additional","affiliation":[{"name":"Department of Medicine I\u2014Angiology, G\u00f6ttlicher Heiland Hospital Vienna , 1170 Vienna ,","place":["Austria"]},{"name":"Division of Angiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, 1090 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"2026092113343081200_zwag481-B1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Boren","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"2026092113343081200_zwag481-B3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B4","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B5","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B6","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"Ageno","year":"2008","journal-title":"Circulation"},{"key":"2026092113343081200_zwag481-B8","author":"European Society of Cardiology"},{"key":"2026092113343081200_zwag481-B9","doi-asserted-by":"crossref","first-page":"18028","DOI":"10.1038\/nrdp.2018.28","article-title":"Pulmonary embolism","volume":"4","author":"Huisman","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026092113343081200_zwag481-B10","doi-asserted-by":"crossref","first-page":"15006","DOI":"10.1038\/nrdp.2015.6","article-title":"Venous thrombosis","volume":"1","author":"Wolberg","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2026092113343081200_zwag481-B11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026092113343081200_zwag481-B12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2213-2600(19)30354-6","article-title":"Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database","volume":"8","author":"Barco","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026092113343081200_zwag481-B13","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/archinte.164.20.2260","article-title":"Venous thromboembolism according to age: the impact of an aging population","volume":"164","author":"Stein","year":"2004","journal-title":"Arch Intern Med"},{"key":"2026092113343081200_zwag481-B14","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1001\/archinte.164.16.1804","article-title":"Pulmonary thromboembolism in American Indians and Alaskan Natives","volume":"164","author":"Stein","year":"2004","journal-title":"Arch Intern Med"},{"key":"2026092113343081200_zwag481-B15","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/j.1538-7836.2010.03986.x","article-title":"Venous thrombosis in the elderly: incidence, risk factors and risk groups","volume":"8","author":"Engbers","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B16","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjmed.2019.03.021","article-title":"Reasons for differences in the incidence of venous thromboembolism in black versus white Americans","volume":"132","author":"Folsom","year":"2019","journal-title":"Am J Med"},{"key":"2026092113343081200_zwag481-B17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12185-023-03651-6","article-title":"Current challenges in the prevention and management of post-thrombotic syndrome-towards improved prevention","volume":"118","author":"Wang","year":"2023","journal-title":"Int J Hematol"},{"key":"2026092113343081200_zwag481-B18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00063198-200109000-00015","article-title":"Prevention of venous thromboembolism in trauma and long bone fractures","volume":"7","author":"Hak","year":"2001","journal-title":"Curr Opin Pulm Med"},{"key":"2026092113343081200_zwag481-B19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.4065\/76.11.1102","article-title":"Incidence of venous thromboembolism in hospitalized patients vs community residents","volume":"76","author":"Heit","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"2026092113343081200_zwag481-B20","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/archinte.167.14.1471","article-title":"Venous thromboembolism in the outpatient setting","volume":"167","author":"Spencer","year":"2007","journal-title":"Arch Intern Med"},{"key":"2026092113343081200_zwag481-B21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"key":"2026092113343081200_zwag481-B22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archinternmed.2007.5","article-title":"Minor injuries as a risk factor for venous thrombosis","volume":"168","author":"van Stralen","year":"2008","journal-title":"Arch Intern Med"},{"key":"2026092113343081200_zwag481-B23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/a-2178-6574","article-title":"Management of deep vein thrombosis: an update based on the revised AWMF S2k guideline","volume":"44","author":"Linnemann","year":"2024","journal-title":"Hamostaseologie"},{"key":"2026092113343081200_zwag481-B24","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/eurjpc\/zwab088","article-title":"Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function","volume":"29","author":"Mazzolai","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026092113343081200_zwag481-B25","doi-asserted-by":"crossref","first-page":"1901647","DOI":"10.1183\/13993003.01647-2019","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)","volume":"54","author":"Konstantinides","year":"2019","journal-title":"Eur Respir J"},{"key":"2026092113343081200_zwag481-B26","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001018","article-title":"Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials","volume":"10","author":"Adelhelm","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2026092113343081200_zwag481-B27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"2026092113343081200_zwag481-B28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"2026092113343081200_zwag481-B29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"key":"2026092113343081200_zwag481-B30","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.109.925214","article-title":"Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model","volume":"121","author":"Eichinger","year":"2010","journal-title":"Circulation"},{"key":"2026092113343081200_zwag481-B31","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/jth.13781","article-title":"External validation of the DASH prediction rule: a retrospective cohort study","volume":"15","author":"Tosetto","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B32","article-title":"Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study","volume":"356","author":"Rodger","year":"2017","journal-title":"BMJ"},{"key":"2026092113343081200_zwag481-B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S4780","article-title":"Venous and arterial thrombosis: two aspects of the same disease?","volume":"1","author":"Prandoni","year":"2009","journal-title":"Clin Epidemiol"},{"key":"2026092113343081200_zwag481-B34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/cells14020144","article-title":"The link between venous and arterial thrombosis: is there a role for endothelial dysfunction?","volume":"14","author":"Donadini","year":"2025","journal-title":"Cells"},{"key":"2026092113343081200_zwag481-B35","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1038\/s41598-020-59526-x","article-title":"The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli","volume":"10","author":"Chernysh","year":"2020","journal-title":"Sci Rep"},{"key":"2026092113343081200_zwag481-B36","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3390\/ijms17101723","article-title":"The inflammatory role of platelets: translational insights from experimental studies of autoimmune disorders","volume":"17","author":"Pankratz","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2026092113343081200_zwag481-B37","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1161\/CIRCULATIONAHA.109.921460","article-title":"Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study","volume":"121","author":"Holst","year":"2010","journal-title":"Circulation"},{"key":"2026092113343081200_zwag481-B38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1160\/TH11-10-0726","article-title":"Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis","volume":"108","author":"Wattanakit","year":"2012","journal-title":"Thromb Haemost"},{"key":"2026092113343081200_zwag481-B39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","article-title":"Cardiovascular risk factors associated with venous thromboembolism","volume":"4","author":"Gregson","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026092113343081200_zwag481-B40","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa022157","article-title":"An association between atherosclerosis and venous thrombosis","volume":"348","author":"Prandoni","year":"2003","journal-title":"N Engl J Med"},{"key":"2026092113343081200_zwag481-B41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2005.03.047","article-title":"Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism","volume":"183","author":"Hong","year":"2005","journal-title":"Atherosclerosis"},{"key":"2026092113343081200_zwag481-B42","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf747","article-title":"Arterial cardiovascular disease risk after venous thromboembolism in young adults: a Danish Nationwide Cohort Study","author":"Scheres","journal-title":"Eur J Prev Cardiol"},{"key":"2026092113343081200_zwag481-B43","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1093\/eurheartj\/ehab495","article-title":"Chronic venous insufficiency, cardiovascular disease, and mortality: a population study","volume":"42","author":"Prochaska","year":"2021","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.thromres.2021.05.009","article-title":"Frequency and incidence of arterial events in patients with venous thromboembolism compared to the general population: a systematic review and meta-analysis of cohort studies","volume":"203","author":"Noumegni","year":"2021","journal-title":"Thromb Res"},{"key":"2026092113343081200_zwag481-B45","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1538-7836.2010.03777.x","article-title":"Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis","volume":"8","author":"Becattini","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/eurheartj\/ehi018","article-title":"A prospective study on cardiovascular events after acute pulmonary embolism","volume":"26","author":"Becattini","year":"2005","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B47","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.117.031062","article-title":"Frequency, predictors, and impact of combined antiplatelet therapy on venous thromboembolism in patients with symptomatic atherosclerosis","volume":"137","author":"Cavallari","year":"2018","journal-title":"Circulation"},{"key":"2026092113343081200_zwag481-B48","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2026092113343081200_zwag481-B49","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.122.059405","article-title":"Rivaroxaban 2.5 mg twice daily plus aspirin reduces venous thromboembolism in patients with chronic atherosclerosis","volume":"145","author":"Pogosova","year":"2022","journal-title":"Circulation"},{"key":"2026092113343081200_zwag481-B50","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15580","article-title":"Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization","volume":"5","author":"Hess","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026092113343081200_zwag481-B51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/eurheartj\/ehab816","article-title":"Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society","volume":"43","author":"Klok","year":"2022","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B52","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jtha.2023.02.023","article-title":"Major acute cardiovascular events after venous thromboembolism: a meta-analysis of randomized trials","volume":"21","author":"Becattini","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0049-3848(97)00192-8","article-title":"Hypercholesterolemia as a risk factor for deep-vein thrombosis","volume":"88","author":"Kawasaki","year":"1997","journal-title":"Thromb Res"},{"key":"2026092113343081200_zwag481-B54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1365-2141.2002.03563.x","article-title":"Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors","volume":"118","author":"Vaya","year":"2002","journal-title":"Br J Haematol"},{"key":"2026092113343081200_zwag481-B55","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinte.162.10.1182","article-title":"Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology","volume":"162","author":"Tsai","year":"2002","journal-title":"Arch Intern Med"},{"key":"2026092113343081200_zwag481-B56","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2008-05-157412","article-title":"High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE)","volume":"112","author":"Chamberlain","year":"2008","journal-title":"Blood"},{"key":"2026092113343081200_zwag481-B57","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1538-7836.2009.03302.x","article-title":"Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women","volume":"7","author":"Everett","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B58","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1538-7836.2009.03481.x","article-title":"HDL-cholesterol and future risk of venous thromboembolism: the Tromso Study","volume":"7","author":"Braekkan","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B59","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ajcnut.2025.08.008","article-title":"High concentrations of polyunsaturated n-3 fatty acids in serum are inversely associated with risk of future incident venous thromboembolism\u2014the HUNT cohort study","volume":"122","author":"Johansson","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"2026092113343081200_zwag481-B60","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1055\/s-0036-1598002","article-title":"Lipoprotein(a) as a risk factor for venous thromboembolism: a systematic review and meta-analysis of the literature","volume":"43","author":"Dentali","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"2026092113343081200_zwag481-B61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/14017431.2019.1612087","article-title":"Lipoprotein(a) is not associated with venous thromboembolism risk","volume":"53","author":"Kunutsor","year":"2019","journal-title":"Scand Cardiovasc J"},{"key":"2026092113343081200_zwag481-B62","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/eurheartj\/ehag252","article-title":"Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men","volume":"47","author":"Ezzat","year":"2026","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B63","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehag263","article-title":"Two to Tango: lipoprotein(a) and hormonal status as determinants of venous thromboembolism risk","volume":"47","author":"Taub","year":"2026","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B64","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/eurheartj\/ehp556","article-title":"Statins, fibrates, and venous thromboembolism: a meta-analysis","volume":"31","author":"Squizzato","year":"2010","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B65","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1742-1241.2010.02439.x","article-title":"Statin use and the prevention of venous thromboembolism: a meta-analysis","volume":"64","author":"Agarwal","year":"2010","journal-title":"Int J Clin Pract"},{"key":"2026092113343081200_zwag481-B66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001310","article-title":"Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials","volume":"9","author":"Rahimi","year":"2012","journal-title":"PLoS Med"},{"key":"2026092113343081200_zwag481-B67","article-title":"Statins for primary prevention of venous thromboembolism","volume":"2014","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026092113343081200_zwag481-B68","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2352-3026(16)30184-3","article-title":"Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis","volume":"4","author":"Kunutsor","year":"2017","journal-title":"Lancet Haematol"},{"key":"2026092113343081200_zwag481-B69","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) inhibition on the Risk of Venous Thromboembolism","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"2026092113343081200_zwag481-B70","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2021.106931","article-title":"Effects of statins in primary and secondary prevention for venous thromboembolism events: a meta analysis","volume":"142","author":"Zhu","year":"2022","journal-title":"Vascul Pharmacol"},{"key":"2026092113343081200_zwag481-B71","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4274\/balkanmedj.galenos.2023.2023-5-26","article-title":"Risk of venous thromboembolism with statins: evidence gathered via a network meta-analysis","volume":"40","author":"Birdal","year":"2023","journal-title":"Balkan Med J"},{"key":"2026092113343081200_zwag481-B72","article-title":"Statins for the primary prevention of venous thromboembolism","volume":"11","author":"Wang","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026092113343081200_zwag481-B73","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1093\/eurheartj\/ehae361","article-title":"Lipid lowering for prevention of venous thromboembolism: a network meta-analysis","volume":"45","author":"Farmakis","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B74","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"2026092113343081200_zwag481-B75","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/cvr\/cvab078","article-title":"Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials","volume":"118","author":"Joseph","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026092113343081200_zwag481-B76","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/eurheartj\/ehae492","article-title":"From arteries to veins: the expanding role of lipid-lowering drugs in preventing thrombosis","volume":"45","author":"Nopp","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B77","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.9467","article-title":"Low-density lipoprotein cholesterol levels and bleeding risk in venous thromboembolism","volume":"8","author":"Siniscalchi","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026092113343081200_zwag481-B78","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamacardio.2026.1208","article-title":"Bempedoic acid and venous thromboembolism risk among statin-intolerant patients: a post hoc analysis of the CLEAR outcomes randomized clinical trial","volume":"11","author":"Spiazzi","year":"2026","journal-title":"JAMA Cardiol"},{"key":"2026092113343081200_zwag481-B79","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2026092113343081200_zwag481-B80","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/eurheartj\/ehx107","article-title":"Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies","volume":"38","author":"Kunutsor","year":"2017","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B81","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105413","article-title":"Effect of statins on the risk of recurrent venous thromboembolism: a systematic review and meta-analysis","volume":"165","author":"Li","year":"2021","journal-title":"Pharmacol Res"},{"key":"2026092113343081200_zwag481-B82","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/jth.15752","article-title":"Statin therapy in venous thromboembolism: how far from primary and secondary prevention?","volume":"20","author":"Jiang","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B83","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/jth.13334","article-title":"The association of statin therapy with the risk of recurrent venous thrombosis","volume":"14","author":"Smith","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/rth2.12003","article-title":"Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study","volume":"1","author":"Braekkan","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"2026092113343081200_zwag481-B85","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1055\/s-0040-1716734","article-title":"Different types of statins and all-cause mortality during anticoagulation for venous thromboembolism: validation study from RIETE registry","volume":"4","author":"Siniscalchi","year":"2020","journal-title":"TH Open"},{"key":"2026092113343081200_zwag481-B86","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s11239-024-03002-0","article-title":"Statins use and recurrent venous thromboembolism in the direct oral anticoagulant era: insight from the COMMAND VTE Registry-2","volume":"57","author":"Mabuchi","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"2026092113343081200_zwag481-B87","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.thromres.2012.08.296","article-title":"Lipid lowering drugs and the risk of recurrent venous thromboembolism","volume":"130","author":"Delluc","year":"2012","journal-title":"Thromb Res"},{"key":"2026092113343081200_zwag481-B88","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1538-7836.2009.03282.x","article-title":"A new indication for statins to prevent venous thromboembolism? Not yet","volume":"7","author":"Cushman","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B89","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/jth.15626","article-title":"Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: a randomized controlled trial","volume":"20","author":"Ramberg","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026092113343081200_zwag481-B90","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2004-11-4230","article-title":"LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo","volume":"106","author":"Bovenschen","year":"2005","journal-title":"Blood"},{"key":"2026092113343081200_zwag481-B91","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1093\/eurheartj\/ehaa842","article-title":"The cardiovascular benefit of Lp(a) reduction: not there yet","volume":"41","author":"Pirillo","year":"2020","journal-title":"Eur Heart J"},{"key":"2026092113343081200_zwag481-B92","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40256-021-00499-1","article-title":"A review of the clinical pharmacology of pelacarsen: a lipoprotein(a)-lowering agent","volume":"22","author":"Hardy","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026092113343081200_zwag481-B93","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411739","article-title":"The effects of statins, ezetimibe, PCSK9-inhibitors, inclisiran, and icosapent ethyl on platelet function","volume":"24","author":"Di Costanzo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026092113343081200_zwag481-B94","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH03-02-0111","article-title":"Platelet hyperactivity after statin treatment discontinuation","volume":"90","author":"Puccetti","year":"2003","journal-title":"Thromb Haemost"},{"key":"2026092113343081200_zwag481-B95","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/jcdd12090355","article-title":"The effects of inclisiran on the subclinical prothrombotic and platelet activation markers in patients at high cardiovascular risk","volume":"12","author":"Malig\u0142\u00f3wka","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026092113343081200_zwag481-B96","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4244\/EIJ-D-22-00719","article-title":"Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study","volume":"18","author":"Franchi","year":"2023","journal-title":"EuroIntervention"},{"key":"2026092113343081200_zwag481-B97","doi-asserted-by":"crossref","first-page":"676","DOI":"10.14740\/jocmr3901","article-title":"Ezetimibe monotherapy reduces serum levels of platelet-activating factor acetylhydrolase in patients with dyslipidemia","volume":"11","author":"Tano","year":"2019","journal-title":"J Clin Med Res"},{"key":"2026092113343081200_zwag481-B98","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10557-009-6201-8","article-title":"A clinical puzzle: fibrates and homocysteine elevation: editorial to: \u201cfibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine\u201d by M. Lever et al","volume":"23","author":"Davidson","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026092113343081200_zwag481-B99","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag481\/71004335\/zwag481.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag481\/71004335\/zwag481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:34:52Z","timestamp":1790012092000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag481\/8788632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":99,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag481","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"zwag481"}}